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Abstract 
Purpose: To compare oral bioavailability and pharmacokinetic parameters of different lornoxicam 
formulations and to assess similarity in plasma level profiles by statistical techniques.  
Methods: An open-label, two-period crossover trial was followed in 24 healthy Pakistani volunteers (22 
males, 2 females). Each participant received a single dose of lornoxicam controlled release (CR) 
microparticles and two doses (morning and evening) of conventional lornoxicam immediate release (IR) 
tablet formulation. The microparticles were prepared by spray drying method. The formulations were 
administered again in an alternate manner after a washout period of one week. Pharmacokinetic 
parameters were determined by Kinetica 4.0 software using plasma concentration-time data. Moreover, 
data were statistically analyzed at 90 % confidence interval (CI) and Schuirmann’s two one-sided t-test 
procedure.  
Results: Peak plasma concentration (Cmax) was 20.2 % lower for CR formulation compared to IR 
formulation (270.90 ng/ml vs 339.44 ng/ml, respectively) while time taken to attain Cmax (tmax) was 5.25 
and 2.08 h, respectively. Area under the plasma drug level versus time (AUC) curve was comparable for 
both CR and IR formulations. The 90 % confidence interval (CI) values computed for Cmax, AUC0-24, and 
AUC0- , after log transformation, were 87.21, 108.51 and 102.74 %, respectively, and were within pre-
defined bioequivalence range (80 - 125 %).  
Conclusion: The findings suggest that CR formulation of lornoxicam did not change the overall 
pharmacokinetic properties of lornoxicam in terms of extent and rate of lornoxicam absorption.  
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Lornoxicam is a short-acting non-steroidal anti-
inflammatory drug (NSAID) which belongs to the 
oxicam group. It decreases prostaglandin 
production by reducing cyclo-oxygenase (COX) 
activity. It is successfully being used in clinical 
settings for alleviating the symptoms of 
rheumatoid arthritis, osteoarthritis, acute sciatica 
and ankylosing spondylitis. Moreover, it has 
demonstrated comparable analgesic efficacy to 
morphine for relieving postoperative pain [3]. Due 
to short half-life of 3 to 5 h, the drug is highly 
feasible to be formulated as controlled release 
formulation [1,2]. 
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Patient compliance to prescribed regimen of 
NSAIDs in chronic disorders (rheumatoid arthritis 
& ankylosing spondylitis) is generally poor [4]. 
The reasons for low compliance of NSAIDs 
include temporary relief of symptoms and gastric 
irritation associated with frequent intake of 
NSAIDs. Substantial variation in compliance has 
been observed in patients taking NSAIDs 
resulting in poor drug efficacy and safety [5]. 
 
Previous studies have revealed that switching 
from IR to CR formulations reduces the side 
effects as well as improves outcomes of therapy 
[6-8]. However, no report demonstrates in-vivo 
comparative pharmacokinetic analysis for any 
NSAID drug by formulating different release 
formulations. Therefore, an attempt was made to 
compare pharmacokinetic parameters (tmax, Cmax, 
AUC) of newly formulated CR lornoxicam 




Preparation of lornoxicam-loaded 
microparticles 
 
Lornoxicam microencapsulation was achieved by 
spray drying according to the polymer blend 
concentrations specified in table 1. We dissolved 
weighed quantities of polymers in acetone and 
ethanol mixture used in the ratio of 40:60. 
Hydroxy propyl methyl cellulose (HPMC) 15 cps 
was dissolved first in organic mixture followed by 
Eudragit L100 and clear solution was obtained. 
Then drug was added into polymer solution with 
continuous stirring for 45 - 60 min. Finally, drug 
polymer dispersion so prepared was spray-dried 
using Lab scale spray dryer with a nozzle of 2 
mm diameter (YC 1500, Shangai, China). The 
dried particles enclosing core material were 
collected in the bottom of dryer [9]. The 
parameters set for spray drying were as follows: 
Inlet air temperature, 80 – 90 oC; inlet air volume, 
200 - 300m3/h; spray rate, 8-10gm/min; product 
temperature, 40 - 50 oC; and atomizing air 
pressure; 1 bar. 
 
Characterization of microparticles  
 
The formulated microcapsules were 
characterized for morphology, encapsulation 
efficiency, percent drug loading and in-vitro 
dissolution studies as described by Shah et al 
[9]. 
 
Subjects’ inclusion and exclusion criteria 
 
Twenty four healthy subjects {age, 21.69 ± 2.32 
years (range, 17.18 - 26 years); weight, 70.14 ± 
7.98 kg (range, 60.12 - 89 kg); height, 180.25 ± 
7.32 cm (range, 168.2 - 190.93 cm); and BMI, 
21.59 ± 2.04 kg/m2 (range, 18.73 - 24.82 kg/m2)} 
were selected for the study. All the subjects were 
examined to determine their health status based 
on medical history, physical examination, vital 
signs, and laboratory tests (hematology, 
biochemistry, hepatic function, and urinalysis). 
Subjects who had a history of gastric ulcers and 
those receiving oral corticosteroids were not 
included in the study. Written informed consent 
was taken from each participant before the 
commencement of study. They were free to 
withdraw from the study at any time. Physical 
examination took into account normal laboratory 




The present open label, randomized, two-way 
crossover, comparative bioavailability study was 
performed according to the principles of Helsinki 
Declaration (WMA) [10] and Good Clinical 
Practices (GCP) [11]. The study protocols were 
approved by the ethical committee of Human 
Research Review Board of University College of 
Pharmacy, University of the Punjab, Lahore, and 
the guidelines of Helsinki Declaration were 
followed. All the volunteers were fasted overnight 
at least 10 h prior to dosing with water as 
desired. Subjects received single dose of CR 
formulation and two doses of IR formulation 
followed by a washout period of 7 days and 
administration of alternate formulations. 
 











   HPMC 
15cps     
(mg) 
AF-1 300 1:1 300 0 
AF-2 300 1:1 0 300 
AF-3 300 1:1 150 150 
AF-4 300 1:1.5 225 225 
AF-5 300 1:2 300 300 
AF-6 300 1:2.5 375 375 
AF-7 300 1:3 450 450 
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Lornoxicam IR formulation was administered 
twice after interval of 12 h in each period. None 
of the participants was on medication of any sort 
which may interfere with the release and 
detection of drugs under study. Standard meal 
was provided after 4 h of drug administration. 
 
Blood sampling and processing 
 
At predetermined time interval, 5ml of blood was 
withdrawn at 0, 0.5, 1, 2, 3, 5, 8, 10, 12, 13, 14, 
15, 18, 20 and 24 h by phlebotomists. 
Disposable 5 ml syringes were used to collect 
blood samples into heparin containing centrifuge 
tubes. The samples, immediate after collection, 
were centrifuged at 4000 rpm for 10 min to 
separate plasma which was carefully conveyed 
to eppendrof tubes using micropipette. The 
prepared plasma samples were kept at oC 
until lornoxicam concentration was estimated by 
bio-analytical HPLC method. 
 
Determination of drug in blood samples 
 
Lornoxicam levels in plasma samples were 
determined by specific and sensitive HPLC 
method. The mobile phase used was mixture of 
phosphate buffer (pH 4.5, adjusted with 
orthophosphoric acid) and acetonitrile (45:55, 
v/v). Freshly prepared mobile phase was 
degassed by vacuum filtration, sonicated and 
pumped with a flow rate of 1 ml/min. After adding 
0.5 ml of methanol, 0.5 ml of trichloroacetic acid 
and 0.5 ml of internal standard solution 
(piroxicam, 20 µg/ml), plasma samples were 
vortex mixed for 3 min and then centrifuged at 
2500 rpm for 5min. Then, samples were placed 
on extrelut-1 columns and dichloromethane (10 
ml) was used to elute lornoxicam. The eluate 
was dehydrated under nitrogen stream (35 oC) 
followed by reconstitution with 40
phase. Finally, after centrifugation at 100 rpm, 50 
system. 
 
HPLC system consisted of hypersil ODS column 
(150 × 4.5 i.d, 5µm particle size, Agilent) for 
carrying out separation. Class GC software was 
connected with variable wavelength UV detector 
for data processing and chromatographic 
integration. An isocratic pump (LC-10 ATVP, 
Shimadzu Corporation, Japan) was used for 




Physical assessment and vital signs (pulse rate, 
blood pressure and body temperature) were 
monitored for each enrolled subject before 
administration of study drugs and during the 
blood sampling. Subjects were continuously 
examined by the physicians throughout the study 
for incidence of adverse effects.  
 
Pharmacokinetic and statistical analyses 
 
The parameters included Cmax, AUC0-24, AUC0- , 
tmax, half-life (t1/2), mean residence time (MRT), 
and elimination rate constant (ke) were 
determined by Kinetica 4.0 (Thermofisher 
Scientific, PK/PD software, USA) for each 
subject. Tmax and Cmax were also estimated 
directly from the constructed plot of plasma 
concentration- time profiles [12,13]. 
 
Significant difference in parameters was 
considered at p < 0.05. Analysis of variance 
(ANOVA) for a crossover (2 × 2) study design 
was calculated by SPSS software (IBM Statistics 
21, USA). The formulations were considered 
comparable if 90 % CI for the geometric mean 
ratios (test: reference) of ln-transformed Cmax, 
AUC0-t, and AUC0-  rest between 0.80 and 1.25 - 
a stipulated criterion of US Food and Drug 
administration [14,15]. Average bioequivalence 
was further confirmed between test and 
reference formulations by applying Schuirmann 




Characteristics of microparticles 
 
The microparticles were ellipsoidal in shape with 
surface morphology clearly showing presence of 
drug particles (Figure 1). The incorporation 
efficiency increased from 56.48 % ± 2.21 to 
83.04 % ± 1.22 with the increase in the polymer 
contents. Percent loading was in the range of 
42.88 % ± 1.4 to 68.35 % ± 1.13 and was 
independent of contents of polymer blend. 
 
The release results showed that burst release 
was reduced in microparticles containing higher 
contents of polymers. This was due to decrease 
in surface associated drug. Microparticle 
formulations containing drug polymer blend in the 
ratio of 1:1 and 1:1.5 released 97.55 ± 3.33 % 
and 92.6 ± 3.92 % of drug, respectively at the 
end of 20 h without subsequent release. 
Similarly, formulation AF-6 liberated maximum 
drug amount of 96.16 ± 3.88 % on the time point 
of 20 h. Only formulation AF-7 (1:3) sharply 
demonstrated drug release of 97.22 ± 3.22 % 
after 24 h that was a typical sustained release 
pattern. Taken together, the release pattern 
clearly showed that rate of drug release but not 
the extent was decreased on increasing amounts 
of polymer matrices. Out of seven formulations, 
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microcapsules of one formulation (AF-7) were 
selected for in-vivo study based on promising 
results in terms of encapsulation efficiency and 
release studies. Moreover, the optimized 
formulation demonstrated near zero order 
kinetics. 
 
Finally, microparticles (AF-7) equivalent to 16 mg 
of lornoxicam were filled in 0 size capsules which 
acted as test formulation. Whilst, reference 
formulation was immediate release film coated 
tablets of lornoxicam (8 mg). The in-vitro release 
profiles of test and reference formulations are 
shown in Figure 2. 
 
 










AF-1 56.48 ± 2.21 28.25 ± 0.2 62.29 ± 1.68 
AF-2 65.52 ± 1.68 32.75 ± 0.2 53.27 ± 2.28 
AF-3 61.04 ± 1.7 30.5 ± 0.1 55.89 ± 1.07 
AF-4 68.1 ± 1.4 27.25 ± 0.3 64.16 ± 0.92 
AF-5 67.59 ± 1.3 22.5 ± 0.4 42.88 ± 1.4 
AF-6 74.27 ± 1.15 21.25 ± 0.1 59.34 ± 1.8 
AF-7 83.04 ± 1.22 20.75 ± 0.2 68.35 ± 1.13 
   
 




Figure 2: In-vitro release profiles of lornoxicam Reference (IR) and test (CR) formulations 
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Validation parameters of developed HPLC 
method 
 
Intra- and inter-day precision and recoveries 
(absolute and relative) of lornoxicam in human 
plasma are shown in Table 2. 
 
Pharmacokinetic properties  
 
The plasma profiles (mean ± SD) of test and 
reference formulations of lornoxicam were 
presented in Figure 3. The main pharmacokinetic 
parameters calculated were summarized in table 
3. The mean (± SD) Cmax values for test and 
reference formulations were 270.90 ± 33 ng/mL 
and 339.44 ± 41.39 ng/mL (p < 0.05), 
respectively. The mean AUC0–t values in the test 
and reference formulations were 2643.03 ± 35.03 
and 2456.62 ± 25.39 ng.h/mL, and the mean 
AUC0-  were 2740.89 ± 33.03 and 2640.98 ± 
27.91 ng.h/mL. The median (range) tmax was 5.3 
(5.20±8.30) and 1.93 (1.60–2.30) hours (p < 
0.05). The ke was 0.115 (0.02) and 0.157 (0.02) 
h–1, and the t1/2 was 6.13 (0.86) and 4.46 (0.45) 
hours (p < 0.05). ANOVA shows no effect of 
sequence or period on the pharmacokinetic 
parameters. Surprisingly, the Cmax for first dose 
of lornoxicam IR formulation was higher than that 
of second dose. This observation might relate to 
the influence of circadian rhythms on the kinetics 
of drugs leading to faster absorption in the 
morning compared with the evening [17]. 
 





Intra-day (n=9)*     Inter-day (n=9)*     Recovery 
Amount 
quantitated     
(µg/ml) 
RSD  %   
Amount 
quantitated          
(µg/ml) 
RSD   %   Absolute Relative 
0.2   0.19±0.09 1.5 0.19±0.06 4.9 89.7±4.5 96.5±5.37 
3 2.99±0.06 2.2 2.93±0.03 2 98.4±3.8 99.6±2.14 
4 4.00±0.13 3.5   3.89±0.08 0.7   100.4±4.0  100±3.1 





         Figure 3: Plasma concentration-time profiles of test and reference formulations 
 
    Table 3: Pharmacokinetic parameters of test and reference formulations (mean ± SD) 
 
Parameter Test (CR) Reference (IR) P-value 
Cmax, ng/ml 270.90±33 339.44±41.39 0.05 
Tmax, h 5.25±0.87 2.08±0.29 0.05 
AUC0-24, ng.h/ml 2643.03±35.03 2414.5±16.37 NS 
AUC0-  2756.4±29.3 2682.8±21.8 NS 
t1/2, h 6.13±0.86 4.46±0.45 0.05 
Ke, h-1 0.115±0.02 0.157±0.03 NS 
MRT, h 14.57±1.42 12.51±0.54 NS 
      ‘NS’ means ‘not significant’ 
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Table 4: 90% CI and ratio for test and reference 







Ln Cmax, ng/ml 87.21 81.91 - 92.51 
Ln AUC0-t, ng.h/ml 108.51 97.70 - 119.33 
Ln AUC 0-  102.74 89.50 - 115.98 
Ln= natural logarithm 
 
Table 5: Schuirmann two 1-sided t-tests for 
comparative analysis of CR and IR lornoxicam 
formulations* 
 
Parameter TL TU t (0.05-22 df)* 
Cmax, ng/ml 21.47 62.03 1.7171 
AUC0-24, ng.h/ml 74.64 136.5 1.7171 
AUC0- , ng.h/ml 4.88 142.32 1.7171 
T- t statistic; TL-lower T; TU-upper T; df-degrees of 
freedom; *Criteria: If TL (0.05–22 df) and TU 
(0.05–22 df), then bioequivalence can be deduced. If 
TL –22 df) or TU –22 df), then 
bioequivalence cannot be established between 
formulations 
 
Comparative pharmacokinetic profile 
 
The analysis of 90 %CI of Cmax, AUC0-t, and 
AUC0-  values for the test and reference 
formulations were 81.21 to 92.51 %, 97.70 to 
119.33 %, and 89.50 to 115.98 %, respectively 
and were listed in Table 4. The values were well 
within acceptable bioequivalence criteria (80 - 
125 %). The relative bioavailability of lornoxicam 
was 107.62 %. The findings of Schuirmann test 





Mild gastrointestinal problem (nausea) occurred 
in couple of volunteers receiving IR tablet during 
the second period of the study. Literature survey 
revealed that this mild side effect was associated 
with Lornoxicam salt (chlortenoxicam). The 
problem was immediately overcome by 
appropriate action of clinician and the subject 
successfully completed the study. CR formulation 
was found to lessen the side effects (nausea, 
diarrhea) of the salt as no active complaint was 
noticed from participants taking CR formulations. 
No other treatment related adverse event was 




This study demonstrated the bioequivalence of 
two oral formulations of lornoxicam - a newly 
developed CR microcapsule formulation and a 
marketed IR tablet - in healthy Pakistani 
volunteers. AUC0-t and AUC0-  are indicators of 
total amount of absorption, Cmax reflects both 
extent and rate of absorption, and tmax shows 
rate of absorption and elimination [18,19]. The 
Cmax and tmax of the marketed lornoxicam tablet 
(reference) were comparable with previous 
reports [20,21]. The comparable Cmax, AUC0–24 
and AUC0–  for lornoxicam CR and IR 
formulations showed that both formulations had 
similar apparent oral clearance. As expected, it 
was observed that transforming the dosage 
forms did not change total absorption of 
lornoxicam even with dose administered once. 
Moreover, a significant drop of 20.2 % in the 
mean value of Cmax was observed for lornoxicam 
CR formulation than for lornoxicam IR (270.90 ± 
33 ng/mL and 339.44 ± 41 ng/mL, respectively). 
This pattern clearly indicates controlled release 
of lornoxicam from microparticles. Furthermore, 
these findings proposed that, at steady state, 
lornoxicam CR and IR formulations will 
demonstrate comparable bioavailability when 
administered at the same daily dose (16 
mg/day). A considerable difference was seen in 
the values of t1/2 and ke between the test and 
reference formulations, further corroborating the 
profound effect on parameters due to 
modification in the formulation. 
 
The time to reach Cmax (tmax) was 5.30 h for 
lornoxicam CR compared with 2.0 h for 
lornoxicam IR. In future, such delay in action can 
be avoided by incorporation of small IR fraction 
in microparticle dosage form. The longer 
elimination half-life of single CR dose compared 
with twice-dose of IR formulation (6.13 ± 0.86 h 
vs 4.46 ± 0.45 h, respectively) suggested that 
controlled release formulation is suitable for once 
daily dosing. 
 
The geometric mean of lornoxicam 
CR/lornoxicam IR ratio for Cmax, AUC0–t and 
AUC0-   were 87.21, 108.51 and 102.74 (90 % 
CIs 81.91 ± 92.51 %, 97.7 ± 119.3 % and 89.5 ± 
115.98 % respectively), which were within 
bioequivalence pre-defined range (80 %–125 %) 
with respect to total amount of lornoxicam. 
 
The study has some limitations as the 
pharmacokinetic data were obtained from healthy 
Pakistani volunteers so the findings of the study 
cannot be generalized to all patient populations. 
Furthermore, serum concentrations of 5-
hydroxylornoxicam were not measured due to 
lack of clinical significance. Small sample size 
and open-label design were also study 
limitations. 
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The findings of this non-replicated crossover 
study demonstrates that test lornoxicam 
microparticulate (CR capsules, OD) and 
reference (IR tablet, BD) formulations at the 
same molar dose of 16 mg possess comparable 
pharmacokinetic properties. The good controlled 
release properties of the microparticle 
formulation produced by spray drying 
recommend this approach for the design of once-
daily administration of the drug to achieve 
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